Want to take quizzes and track your credits?
Schools reopened in Israel on September 1, 2020, following summer vacation during active SARS-CoV-2 spread when the incidence of new cases of COVID-19 in Israel was one of the highest in the world. During September 2020, COVID-19 cases further surged in Israel, resulting in school closure (September 14), and a countrywide lockdown. Schools were reopened on November 1. We examined the dynamics in infection rates in children and youths aged 0 to 19 years compared with other age groups, with the goal of understanding whether school reopening was associated with SARS-CoV-2 infection in those aged 0 to 9 years.
Sign in to take quiz and track your certificates
CME Disclosure Statement: Unless noted, all individuals in control of content reported no relevant financial relationships. If applicable, all relevant financial relationships have been mitigated.
Accepted for Publication: March 1, 2021.
Published: April 26, 2021. doi:10.1001/jamanetworkopen.2021.7105
Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2021 Somekh I et al. JAMA Network Open.
Corresponding Author: Eli Somekh, MD, Department of Pediatrics, Mayanei Hayeshuah Medical Center, 17 Povarski St, Bnei Brak, Israel (firstname.lastname@example.org).
Author Contributions: Drs I. Somekh and E. Somekh had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: I. Somekh, Simões, E. Somekh.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: I. Somekh, Keinan Boker, Simões, E. Somekh.
Critical revision of the manuscript for important intellectual content: I. Somekh, Shohat, Pettoello-Mantovani, Simões, E. Somekh.
Statistical analysis: I. Somekh, Simões, E. Somekh.
Obtained funding: I. Somekh.
Administrative, technical, or material support: I. Somekh.
Supervision: Keinan Boker, Pettoello-Mantovani, E. Somekh.
Conflict of Interest Disclosures: Dr Simões reported receiving grants, personal fees and travel reimbursement from Astra Zeneca Inc; grants, personal fees, and travel reimbursement from Merck & Co; grants, personal fees, and travel reimbursement from from Regeneron Inc; grants, personal fees, and travel reimbursement from Pfizer Inc, personal fees, and travel reimbursement from Abbvie Inc; personal fees from Alere Inc; grants, personal fees, and travel reimbursement from Roche Inc; served on the Data and Safety Monitoring Board for GlaxoSmithKline Inc; grants from Johnson & Johnson; grants and travel reimbursement from Novavax Inc, outside the submitted work.
Funding/Support: This research was supported by the Ministry of Science & Technology, Israel (grant number 3-16983).
Role of the Funder/Sponsor: The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
You currently have no searches saved.
You currently have no courses saved.